Cargando…

AI-powered drug repurposing for developing COVID-19 treatments

Emerging infectious diseases are an ever-present threat to public health, and COVID-19 is the most recent example. There is an urgent need to develop a robust framework to combat the disease with safe and effective therapeutic options. Compared to de novo drug discovery, drug repurposing may offer a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhichao, Chen, Xi, Carter, Wendy, Moruf, Alicia, Komatsu, Takashi E., Pahwa, Sonia, Chan-Tack, Kirk, Snyder, Kevin, Petrick, Nicholas, Cha, Kenny, Lal-Nag, Madhu, Hatim, Qais, Thakkar, Shraddha, Lin, Yu, Huang, Ruili, Wang, Dong, Patterson, Tucker A., Tong, Weida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865759/
http://dx.doi.org/10.1016/B978-0-12-824010-6.00005-8
Descripción
Sumario:Emerging infectious diseases are an ever-present threat to public health, and COVID-19 is the most recent example. There is an urgent need to develop a robust framework to combat the disease with safe and effective therapeutic options. Compared to de novo drug discovery, drug repurposing may offer a lower-cost and faster drug discovery paradigm to explore potential treatment options of existing drugs. This chapter elucidates the advantages of artificial intelligence (AI) in enhancing the drug repurposing process from a data science perspective, using COVID-19 as an example. First, we elaborate on how AI-powered drug repurposing benefits from the accumulated data and knowledge of COVID-19 natural history and pathogenesis. Second, we summarize the pros and cons of AI-powered drug repurposing strategies to facilitate fit-for-purpose selection. Finally, we outline challenges of AI-powered drug repurposing from a regulatory perspective and suggest some potential solutions.